Recombinant Human Transmembrane protein PVRIG (PVRIG)-VLPs

What is PVRIG and what is its biological significance in immune regulation?

PVRIG (Poliovirus Receptor-Related Immunoglobulin domain-containing protein), also known as CD112R, is an inhibitory immune checkpoint receptor that competes with DNAM-1/CD226 for binding to CD112. PVRIG is predominantly expressed on T cells, natural killer (NK) cells, and NKT cells, playing a crucial role in immune system regulation .

The biological significance of PVRIG lies in its function as an inhibitory receptor. Research has demonstrated that PVRIG is co-expressed with other checkpoint molecules like PD-1 and TIGIT on tumor-infiltrating lymphocytes (TILs) in various cancer types. This co-expression pattern suggests PVRIG's involvement in immune suppression within the tumor microenvironment, making it a potentially valuable target for cancer immunotherapy approaches .

What are Virus-Like Particles (VLPs) and how are they utilized for membrane protein expression?

Virus-Like Particles (VLPs) are hollow protein particles that structurally resemble natural viruses but lack viral genetic material. With diameters ranging from 20-200 nm, VLPs possess regular spatial structures and superior biocompatibility. Despite their structural similarity to viruses, VLPs contain no nucleic acids required for viral replication, eliminating infection risks associated with incomplete viral inactivation, genome exchange, recombination, or atavism .

For membrane protein expression, VLPs provide an exceptional platform. Membrane Protein VLPs (MP-VLPs) are produced by co-expressing the retroviral structural core polyprotein (gag) and the target membrane protein. The retroviral gag core proteins self-assemble at the plasma membrane and bud from host cells that are overexpressing the membrane protein of interest, forming MP-VLPs with a diameter of approximately 150 nm. This approach enables the display of membrane proteins in their native conformation at high copy numbers on the VLP surface .

What are the key advantages of expressing PVRIG in VLP systems compared to traditional expression methods?

Expressing PVRIG in VLP systems offers several distinct advantages over traditional membrane protein expression methods:

• Native conformation preservation: VLPs ensure that PVRIG maintains its natural transmembrane conformation, significantly improving the success rate of isolating antibodies that can recognize the native protein structure .

• Higher antigen abundance: The concentration of target antigen (PVRIG) in encapsulated VLPs is substantially higher than in overexpressed cell systems, providing more robust material for downstream applications .

• Enhanced immunogenicity: The particulate nature of VLPs inherently stimulates stronger immune responses, making PVRIG-VLPs especially valuable for antibody production and immunological studies .

• Optimal size for immune cell interactions: With diameters of 100-300 nm, PVRIG-VLPs are ideally sized for interactions with dendritic cells and are suitable for phage display applications in vivo .

• Versatility in applications: PVRIG-VLPs can be utilized for immunization, ELISA, SPR/BLI, cell experiments, and CAR detection - providing a single platform for multiple research applications .

• Expression in mammalian systems: Using HEK293 expression systems ensures proper post-translational modifications, resulting in PVRIG protein that closely resembles native forms and exhibits greater biological relevance .

What are the critical parameters for optimizing PVRIG-VLP expression and purification?

The optimization of PVRIG-VLP expression and purification requires careful attention to several critical parameters:

Expression System Selection:

• HEK293 cells represent the gold standard for PVRIG-VLP production, as they ensure proper folding and post-translational modifications crucial for preserving PVRIG's native structure and function .

• Alternative systems such as insect cells may be considered for higher yield, though potentially with altered glycosylation patterns.

Co-expression Ratio Optimization:

• The ratio between gag polyprotein and PVRIG constructs is crucial for proper VLP formation.

• A recommended starting point is 1:1, with subsequent optimization based on VLP yield and PVRIG incorporation efficiency.

Culture Conditions:

• Temperature: 32-37°C (lower temperatures may improve protein folding)

• pH: 7.0-7.4

• Dissolved oxygen: 30-50%

• Cell density at transfection: 1-2 × 10^6 cells/mL

Purification Strategy:

• Initial clarification via low-speed centrifugation (1000-2000×g)

• VLP concentration by ultracentrifugation (100,000×g) or tangential flow filtration

• Purification using sucrose density gradient ultracentrifugation (20-60% sucrose)

• Final polishing via size exclusion chromatography

Quality Control Parameters:

• Protein concentration determination using BCA method

• Particle homogeneity assessment via SEC-HPLC or Dynamic Light Scattering

• Functional validation through binding assays with known PVRIG ligands

How can Surface Plasmon Resonance (SPR) be optimized for analyzing PVRIG-VLP interactions with potential binding partners?

Surface Plasmon Resonance (SPR) optimization for PVRIG-VLP interaction analysis requires methodical parameter adjustment:

Immobilization Strategy:

• Direct immobilization: PVRIG-Fc fusion protein can be immobilized on a CM5 sensor chip according to manufacturer's instructions, allowing for controlled orientation .

• Capture approach: Anti-Fc antibodies can be immobilized, followed by capturing PVRIG-Fc, providing more homogeneous presentation.

Experimental Conditions:

• Temperature: 25°C is optimal for most PVRIG interaction studies .

• Flow rate: 30 μL/min provides good mass transport without excessive sample consumption .

• Running buffer: HBS-EP+ (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% v/v surfactant P20, pH 7.4)

Regeneration Protocol:

• 50 mM NaOH provides effective regeneration without damaging the immobilized PVRIG .

• Multiple short pulses may be preferable to a single longer exposure.

Analyte Concentration Range:

• A minimum of five concentrations spanning 0.1-10× the expected KD

• Include buffer blanks and reference protein controls

Data Analysis Approach:

• Use reference-subtracted sensorgrams

• Apply appropriate binding models (1:1, heterogeneous ligand, etc.)

• Analyze both kinetic (ka, kd) and steady-state parameters

Validation Methods:

• Confirm specificity using blocking antibodies

• Perform reverse orientation experiments

• Conduct competitive binding studies with soluble CD112

Example SPR Workflow for PVRIG-VLP Analysis:

• Immobilize PVRIG-Fc on CM5 chip (2000-3000 RU)

• Flow PVRIG-VLPs or control VLPs at increasing concentrations

• Allow association (3-5 min) and dissociation (5-10 min)

• Regenerate surface with 50 mM NaOH

• Process data using Biacore Evaluation software

What analytical techniques provide the most comprehensive characterization of PVRIG-VLP quality and functionality?

A comprehensive characterization strategy for PVRIG-VLPs requires multiple complementary analytical techniques:

Physical Characterization:

Biochemical Characterization:

Functional Analysis:

Advanced Spectroscopic Methods:

• Raman spectroscopy can provide detailed structural information and monitor VLP precipitation

• Circular Dichroism (CD) spectroscopy assists in secondary structure analysis

• Fourier-Transform Infrared Spectroscopy (FTIR) helps characterize protein folding

For optimal characterization, implement a staged approach beginning with physical assessment, followed by biochemical verification, and concluding with functional validation to ensure PVRIG-VLPs meet required quality specifications .

How can PVRIG-VLPs be utilized to investigate checkpoint blockade mechanisms in cancer immunotherapy?

PVRIG-VLPs provide a versatile platform for investigating checkpoint blockade mechanisms in cancer immunotherapy through several methodological approaches:

Binding Assays and Epitope Mapping:
PVRIG-VLPs present the protein in its native conformation, enabling researchers to screen checkpoint inhibitors for binding affinity and epitope specificity. Using techniques like SPR, researchers can characterize antibody-PVRIG interactions with precise kinetic parameters, identifying candidates that block CD112 binding without disrupting protein structure .

Cell-Based Functional Assays:
PVRIG-VLPs can be incorporated into in vitro T cell and NK cell activation assays to evaluate the functional consequences of checkpoint inhibition. By comparing immune cell activation in the presence of PVRIG-VLPs with and without blocking antibodies, researchers can quantify the inhibitory potential of PVRIG and assess the efficacy of candidate therapeutics .

Combinatorial Checkpoint Blockade Studies:
Research has demonstrated that PVRIG is co-expressed with PD-1 and TIGIT on tumor-infiltrating lymphocytes, suggesting potential for combinatorial approaches. PVRIG-VLPs enable controlled studies of how simultaneous blockade of multiple checkpoints affects immune cell function. Studies have shown that combined blockade of PVRIG and PD-L1 provides superior tumor control compared to either monotherapy, highlighting the importance of investigating these combinations .

Animal Model Applications:
PVRIG-VLPs can be used to generate anti-PVRIG antibodies for in vivo studies or directly administered in animal models to evaluate immune responses. Data from murine models (MC38 colon cancer, MCA205 fibrosarcoma, and LLC lung cancer) demonstrate that PVRIG blockade slows tumor growth and prolongs survival by inhibiting exhaustion of both NK cells and CD8+ T cells .

Human Xenograft Models:
To bridge preclinical and clinical research, PVRIG-VLPs can be employed in human NK cell- or PBMC-reconstituted xenograft models. Evidence shows that human PVRIG blockade enhances NK cell function and inhibits tumor growth in these models, providing translational insights for clinical development .

What methodological approaches can be used to study the interaction between PVRIG-VLPs and immune cells in the tumor microenvironment?

Studying PVRIG-VLP interactions with immune cells in the tumor microenvironment requires sophisticated methodological approaches:

Ex Vivo Tumor-Infiltrating Lymphocyte Analysis:

• Isolate TILs from patient tumor samples or mouse models

• Co-culture with PVRIG-VLPs with or without blocking antibodies

• Measure activation markers (CD69, CD25), cytokine production (IFNγ, TNFα), and cytotoxic activity

• Analyze by flow cytometry or single-cell sequencing to identify responsive immune cell subsets

Three-Dimensional Co-Culture Systems:

• Develop spheroid models incorporating tumor cells, stromal components, and immune cells

• Add fluorescently-labeled PVRIG-VLPs to track distribution and cellular interactions

• Monitor immune cell migration, infiltration, and functional activity over time

• Evaluate how PVRIG blockade modifies these parameters

Intravital Microscopy:

• Label PVRIG-VLPs with near-infrared fluorophores

• Perform direct imaging of PVRIG-VLP distribution in tumor-bearing animals

• Track interactions with immune cells in real-time

• Assess how PVRIG blockade alters immune cell motility and tumor engagement

Single-Cell Techniques:

• Apply single-cell RNA sequencing to identify transcriptional signatures associated with PVRIG expression

• Use mass cytometry (CyTOF) to simultaneously measure multiple protein markers

• Implement imaging mass cytometry for spatial relationship analysis between PVRIG+ cells and other components of the tumor microenvironment

In Vivo Mechanistic Studies:

• Utilize genetic models (PVRIG-/- mice) to study tumor growth kinetics

• Perform selective depletion of NK cells or CD8+ T cells to determine the relative contribution of each cell type to anti-tumor responses mediated by PVRIG blockade

• Implement adoptive transfer experiments with PVRIG+ versus PVRIG- immune cells

Humanized Mouse Models:

• Reconstitute immunodeficient mice with human immune cells

• Challenge with human tumor xenografts

• Administer PVRIG-VLPs or anti-PVRIG antibodies

• Monitor immune responses and tumor growth

Research has demonstrated that PVRIG blockade enhances anti-tumor immunity through both NK and CD8+ T cell-dependent mechanisms, with evidence that PVRIG blockade can provide therapeutic effects even in the absence of adaptive immunity (demonstrated in Rag1-/- mice) .

How does PVRIG blockade compare with other checkpoint inhibitors (PD-1, TIGIT) in experimental models, and what are the implications for combination therapies?

PVRIG blockade demonstrates distinct and complementary effects compared to other checkpoint inhibitors, with significant implications for combination immunotherapy approaches:

Comparative Efficacy Studies:

Mechanistic Distinctions:
PVRIG blockade uniquely enhances NK cell function, even in the absence of adaptive immunity as demonstrated in Rag1-/- mice. This contrasts with PD-1 inhibition, which primarily affects T cell responses. The mechanistic distinction suggests that PVRIG blockade could be particularly valuable in tumors with limited T cell infiltration or PD-1 inhibitor resistance .

Combination Therapy Findings:
Experimental evidence demonstrates that combined blockade of PVRIG and PD-L1 provides superior tumor control compared to either monotherapy alone. This synergistic effect likely stems from the distinct but complementary immune cell populations activated by each approach .

Co-expression Patterns:
PVRIG is frequently co-expressed with PD-1 and TIGIT on tumor-infiltrating lymphocytes across multiple cancer types. This co-expression pattern provides a biological rationale for combination approaches targeting these pathways simultaneously .

Preclinical Validation in Multiple Models:
Studies using various tumor models (MC38 colon cancer, MCA205 fibrosarcoma, and LLC lung cancer) consistently demonstrate that PVRIG blockade, either through genetic deficiency or antibody-mediated inhibition, slows tumor growth and prolongs survival by inhibiting exhaustion of both NK cells and CD8+ T cells .

Translational Evidence:
Human studies show that antagonistic anti-PVRIG antibodies combined with anti-TIGIT or anti-PD-1 antibodies synergistically improve the effector function of CD3+ TILs isolated from patients with multiple cancer types, suggesting strong translational potential for these combinations .

Future Directions for Combination Approaches:
The evidence suggests that triple combination therapy targeting PVRIG, TIGIT, and PD-1 may provide comprehensive coverage of inhibitory pathways in the tumor microenvironment, potentially overcoming resistance mechanisms observed with single-checkpoint blockade.

How can Raman spectroscopy be optimized as a Process Analytical Technology (PAT) tool for monitoring PVRIG-VLP production?

Raman spectroscopy offers non-destructive, real-time monitoring capabilities for PVRIG-VLP production, with several optimization strategies:

Preprocessing Pipeline Optimization:
Research demonstrates that optimizing the preprocessing pipeline is critical for maximizing the signal-to-noise ratio (SNR) in Raman spectroscopy of VLPs. A comprehensive approach should include:

• Turbidity correction to account for light scattering effects

• Baseline correction to eliminate fluorescence background

• Background correction methods (comparing SS and OPLS-based approaches)

• Savitzky-Golay filtering (SGF) with appropriate derivative parameters

• Spectral cropping to focus on protein-related wavenumber regions

Wavenumber Selection Strategy:
Specific protein-related wavenumbers (830, 850, 1241, 1314, 1341, and 1617 cm-1) that are not affected by ammonium sulfate (AMS) should be targeted for analysis. This selective approach improves model performance compared to using the entire spectrum .

Multivariate Model Selection:
When developing quantitative models for PVRIG-VLP concentration prediction, both Multiple Linear Regression (MLR) and Partial Least Squares (PLS) regression models should be compared. Research indicates that PLS models with optimal preprocessing (including background correction methods like OPLS) can achieve RMSE values of approximately 0.8 g/L, demonstrating good predictive capability .

Calibration Strategy:
For robust PVRIG-VLP monitoring, calibration should incorporate:

• Samples with varying VLP-to-impurity ratios to account for process variability

• Both batch and fed-batch processing conditions

• Cross-validation approaches to ensure model generalizability

• Testing on representative data splits to validate performance

Optimal Spectral Range:
The wavenumber region 800-1800 cm-1 has been identified as most informative for protein monitoring in VLP samples, with further improvement possible by applying second-derivative Savitzky-Golay filtering (SG2) .

Implementation Recommendations:

• Use temperature-controlled sample holders to minimize thermal variation effects

• Implement in-line probes with appropriate focal depth for real-time monitoring

• Develop automated preprocessing pipelines for immediate data interpretation

• Establish decision trees for process interventions based on spectral changes

By implementing these optimization strategies, Raman spectroscopy can serve as an effective PAT tool for monitoring PVRIG-VLP production, enabling real-time quality control and process optimization.

What are the most effective strategies for maintaining the native conformation of PVRIG when expressed in VLP systems?

Maintaining the native conformation of PVRIG in VLP systems requires comprehensive strategies addressing multiple aspects of expression and purification:

Construct Design Optimization:

• Incorporate the full extracellular domain with proper transmembrane region

• Preserve critical disulfide bonds through correct cysteine positioning

• Consider fusion tags that don't interfere with protein folding (e.g., small C-terminal tags)

• Evaluate signal peptide options to ensure proper membrane targeting

Expression System Selection:
HEK293 cells represent the optimal expression system for PVRIG-VLPs as they provide:

• Human-like glycosylation patterns essential for proper folding

• Appropriate chaperone proteins for complex transmembrane protein assembly

• Mammalian-specific post-translational modifications

• Lipid composition similar to human cells

Culture Condition Optimization:

• Temperature reduction to 30-32°C during expression phase

• Addition of chemical chaperones (e.g., 4-PBA, DMSO at low concentrations)

• Controlled induction to prevent protein aggregation

• Supplementation with appropriate cofactors if required

Harvest and Purification Strategies:

• Gentle mechanical disruption methods

• Avoidance of harsh detergents that may disrupt conformation

• Utilization of sucrose cushion ultracentrifugation

• Size exclusion chromatography for final polishing

• Maintenance of physiological pH and ionic strength throughout purification

Stability Enhancement Approaches:

• Addition of stabilizing excipients (e.g., sucrose, trehalose)

• Consideration of point mutations that enhance stability without altering function

• Implementation of controlled lyophilization protocols if required for storage

Conformational Validation Methods:
Multiple orthogonal techniques should be employed to confirm native conformation:

• Binding assays with natural ligands (CD112)

• Conformational antibody recognition

• Circular dichroism spectroscopy

• Limited proteolysis to assess domain folding

• Functional inhibition of immune cell activation

Storage Condition Optimization:

• Determination of optimal buffer composition (pH, ionic strength, additives)

• Establishment of appropriate temperature conditions (typically -80°C for long-term storage)

• Avoidance of freeze-thaw cycles through proper aliquoting

• Protection from oxidation and light exposure

By implementing these comprehensive strategies, researchers can maximize the likelihood of maintaining PVRIG in its native conformation when expressed in VLP systems, ensuring the biological relevance of subsequent experiments .

What emerging technologies might enhance the utility of PVRIG-VLPs for high-throughput screening of potential therapeutic antibodies?

Several emerging technologies show significant promise for enhancing PVRIG-VLP utility in therapeutic antibody screening:

Microfluidic Antibody Screening Platforms:
Integrating PVRIG-VLPs into microfluidic devices enables high-throughput screening of antibody candidates with minimal sample consumption. Droplet-based microfluidics can encapsulate individual antibody-secreting cells with PVRIG-VLPs and fluorescent reporters to rapidly identify functional binding partners. This approach allows for screening millions of antibody candidates in days rather than weeks.

Single B-Cell Technologies:
Advanced single B-cell isolation and antibody sequencing technologies can be combined with PVRIG-VLP probes to identify rare B cells producing anti-PVRIG antibodies with desired characteristics. By fluorescently labeling PVRIG-VLPs, researchers can use flow cytometry to isolate B cells producing antibodies that bind specific epitopes or compete with CD112 binding.

Yeast Display Evolution Systems:
PVRIG-VLPs can serve as selection targets in yeast display evolution systems, where libraries of antibody variants are expressed on yeast cell surfaces and selected for binding to PVRIG-VLPs under increasingly stringent conditions. This approach facilitates affinity maturation and epitope focusing of lead antibody candidates.

AI-Assisted Epitope Mapping:
Machine learning algorithms can analyze binding data from PVRIG-VLP interactions with antibody libraries to predict epitope locations and binding characteristics. This computational approach accelerates the identification of antibodies targeting specific functional domains of PVRIG.

Label-Free Detection Systems:
Emerging label-free technologies like bio-layer interferometry arrays and impedance-based cellular assays can provide real-time, high-throughput screening of PVRIG-VLP interactions with antibody candidates while simultaneously gathering kinetic binding data.

Organ-on-a-Chip Models:
Integration of PVRIG-VLPs into advanced organ-on-a-chip platforms modeling tumor microenvironments enables functional screening of antibody candidates in physiologically relevant settings, providing early insights into potential efficacy.

CRISPR-Engineered Reporter Systems:
CRISPR-modified immune cells expressing fluorescent or luminescent reporters downstream of PVRIG signaling can be used to screen antibodies for functional blockade rather than just binding, enhancing the biological relevance of screening campaigns.

Implementation of these technologies would significantly accelerate the identification and optimization of therapeutic antibodies targeting PVRIG, potentially reducing development timelines and improving candidate quality.

How might PVRIG-VLPs contribute to the development of multi-specific antibodies targeting multiple checkpoint pathways simultaneously?

PVRIG-VLPs offer unique advantages for developing multi-specific antibodies targeting checkpoint pathways:

Structural Template Generation:
PVRIG-VLPs present the protein in its native membrane context, providing essential structural information for designing multi-specific antibodies that can simultaneously engage PVRIG and other checkpoint receptors. This approach ensures that binding domains are oriented correctly to interact with multiple targets in their physiological arrangement.

Co-Expression Systems:
By co-expressing multiple checkpoint receptors (PVRIG, PD-1, TIGIT) on the same VLP surface, researchers can create multi-checkpoint VLPs that mimic the actual co-expression patterns observed on tumor-infiltrating lymphocytes . These particles serve as valuable tools for:

• Screening antibody libraries for candidates binding multiple targets

• Testing binding competition or cooperativity between targets

• Evaluating avidity effects in multi-specific binding

Epitope Mapping for Optimal Domain Selection:
PVRIG-VLPs facilitate precise epitope mapping through techniques like hydrogen-deuterium exchange mass spectrometry or cryo-electron microscopy. This detailed structural information helps identify optimal epitopes for incorporation into multi-specific formats that maintain the blocking function of each domain.

Functional Validation Platforms:
Cell-based assays incorporating PVRIG-VLPs enable functional assessment of multi-specific antibody candidates, measuring their ability to simultaneously block multiple inhibitory pathways and enhance immune cell activation. These assays can be designed to reflect the complex immune checkpoint landscape in tumors.

Methodology for Bispecific Development:
The following workflow demonstrates how PVRIG-VLPs can facilitate bispecific antibody development:

• Generate separate VLP populations displaying either PVRIG or secondary targets (PD-1, TIGIT)

• Screen antibody libraries against each target individually

• Select lead candidates with desirable binding properties

• Engineer bispecific formats incorporating domains from lead candidates

• Test bispecific constructs against co-expressing VLPs to evaluate dual binding

• Validate functional activity in cellular assays

• Optimize leading bispecific candidates for stability and manufacturability

Synergy Assessment:
Research has demonstrated synergistic effects when blocking PVRIG in combination with PD-L1 or TIGIT blockade . PVRIG-VLPs provide platforms to systematically evaluate these synergies across different multi-specific formats and binding configurations, informing optimal design.

Translational Strategy Development:
By incorporating PVRIG-VLPs into ex vivo assays using patient-derived tumor samples, researchers can assess the potential efficacy of multi-specific antibody candidates in clinically relevant settings before advancing to in vivo studies, accelerating translation to clinical applications.

What experimental designs would be most informative for investigating the role of PVRIG-VLPs in modulating NK cell exhaustion in the tumor microenvironment?

Investigating PVRIG's role in NK cell exhaustion requires sophisticated experimental designs:

Ex Vivo NK Cell Exhaustion Models:

• Isolate NK cells from peripheral blood or tumor tissues

• Culture with chronic stimulation (IL-15/IL-12/IL-18) to induce exhaustion

• Monitor PVRIG expression during exhaustion development

• Introduce PVRIG-VLPs at various timepoints

• Assess markers of exhaustion (PD-1, TIGIT, TIM-3)

• Measure functional parameters (cytotoxicity, cytokine production)

• Compare effects of PVRIG-VLPs vs. anti-PVRIG blocking antibodies

In Vivo Tumor Models with NK Cell Tracking:

• Establish tumor models in PVRIG-knockout and wild-type mice

• Adoptively transfer labeled NK cells (e.g., NK cells from PVRIG-/- mice into wild-type hosts)

• Track NK cell infiltration, proliferation, and function in tumors

• Perform selective depletion of NK cells to confirm their contribution to anti-tumor responses

• Collect and analyze tumor-infiltrating NK cells at multiple timepoints for exhaustion markers

• Compare responses to checkpoint blockade in NK-dependent vs. NK-independent tumor models

Humanized Mouse Models for Translational Insights:

• Reconstitute immunodeficient mice with human NK cells

• Challenge with human tumor xenografts (e.g., SW620 colon cancer)

• Treat with PVRIG-VLPs or anti-PVRIG antibodies

• Monitor tumor growth and NK cell phenotype/function

• Compare outcomes with other checkpoint inhibitors (anti-PD-1, anti-TIGIT)

• Harvest tumors for comprehensive immune profiling

Single-Cell Analysis of NK Cell States:

• Perform single-cell RNA-seq on tumor-infiltrating NK cells

• Identify transcriptional signatures associated with PVRIG expression

• Compare exhaustion programs in PVRIG+ vs. PVRIG- NK cells

• Track changes in these signatures following PVRIG blockade

• Develop computational models of NK cell state transitions

Spatial Analysis of PVRIG in the Tumor Microenvironment:

• Apply multiplex immunofluorescence to tumor sections

• Map spatial relationships between PVRIG+ NK cells and other cell types

• Correlate PVRIG expression with exhaustion markers and functional status

• Assess changes in spatial organization following therapeutic intervention

Mechanistic Studies of PVRIG Signaling:

• Develop reporter systems to monitor PVRIG downstream signaling

• Identify key phosphorylation events and transcriptional changes

• Compare signaling in fresh vs. exhausted NK cells

• Determine how PVRIG interacts with other inhibitory receptors

• Investigate potential for signal pathway cross-talk

Comparative Time-Course Experiments:

• Track NK cell exhaustion development over time in presence/absence of PVRIG

• Compare early vs. late PVRIG blockade effects on NK cell recovery

• Determine whether exhaustion states are reversible with PVRIG blockade

• Identify optimal timing for therapeutic intervention

Research has demonstrated that PVRIG is highly expressed on tumor-infiltrating NK cells with exhausted phenotypes, and either PVRIG deficiency or blockade slows tumor growth by inhibiting NK cell exhaustion. Importantly, PVRIG blockade provides therapeutic effects even in the absence of adaptive immunity (Rag1-/- mice), highlighting the critical role of NK cells in mediating these responses .

What are the most common technical challenges in producing high-quality PVRIG-VLPs, and how can they be addressed?

Producing high-quality PVRIG-VLPs presents several technical challenges that require systematic approaches:

Challenge 1: Low Expression Levels

• Solution: Optimize codon usage for the expression host and employ strong promoters specifically effective in mammalian cells.

• Method: Conduct small-scale expression screening with different promoter/enhancer combinations and signal peptides to identify optimal constructs.

• Validation: Compare protein yields by Western blot and functional assays before scaling up production.

Challenge 2: Improper Protein Folding

• Solution: Express PVRIG-VLPs at reduced temperatures (28-32°C) and supplement culture media with chemical chaperones.

• Method: Add 4-phenylbutyric acid (5 mM), glycerol (5%), or low concentrations of DMSO (1-2%) to enhance proper folding.

• Validation: Assess conformational integrity using conformation-specific antibodies or ligand binding assays.

Challenge 3: Heterogeneous VLP Population

• Solution: Implement stringent purification strategies combining multiple techniques.

• Method: Apply sequential purification with ultracentrifugation through sucrose cushions followed by size exclusion chromatography and/or density gradient ultracentrifugation.

• Validation: Confirm homogeneity using dynamic light scattering (DLS) and transmission electron microscopy (TEM) .

Challenge 4: Low PVRIG Incorporation Efficiency

• Solution: Optimize the ratio between PVRIG and gag polyprotein expression.

• Method: Test different transfection ratios of PVRIG:gag plasmids (1:1, 1:2, 1:3, 2:1) to identify optimal incorporation.

• Validation: Quantify PVRIG:gag ratio in purified VLPs using Western blot and mass spectrometry.

Challenge 5: Aggregation During Storage

• Solution: Develop optimized buffer formulations with stabilizing excipients.

• Method: Screen buffer compositions varying pH (6.5-8.0), salt concentration (100-300 mM), and stabilizers (sucrose, trehalose, arginine, glycine).

• Validation: Monitor particle size and homogeneity over time using DLS and functional assays.

Challenge 6: Batch-to-Batch Variability

• Solution: Implement Process Analytical Technology (PAT) for real-time monitoring.

• Method: Utilize Raman spectroscopy for continuous monitoring of VLP precipitation and production .

• Validation: Develop multivariate models (PLS) for predicting VLP quality attributes from spectroscopic data .

Challenge 7: Functional Assessment Limitations

• Solution: Develop comprehensive functional characterization panels.

• Method: Combine binding assays (SPR/BLI) with cell-based functional assays measuring immune cell activation.

• Validation: Compare results with known PVRIG-expressing cell lines and soluble PVRIG proteins.

Challenge 8: Scale-Up Challenges

• Solution: Implement gradual scale-up with consistent process parameters.

• Method: Transition from shake flasks to wave bioreactors maintaining critical process parameters (CPPs).

• Validation: Monitor quality attributes at each scale to ensure consistency.

By systematically addressing these challenges through the proposed solutions, researchers can significantly improve the quality, consistency, and functionality of PVRIG-VLPs for research applications.

How can researchers troubleshoot issues with PVRIG orientation and functionality in VLP systems?

Troubleshooting PVRIG orientation and functionality in VLP systems requires systematic analysis and strategic interventions:

Diagnostic Approach for Orientation Issues:

• Epitope Accessibility Analysis

  • Method: Perform flow cytometry using antibodies targeting different PVRIG epitopes

  • Interpretation: Differential binding of external vs. transmembrane domain antibodies indicates orientation problems

  • Solution: Modify the linker length between PVRIG and membrane anchoring domains

• Protease Protection Assay

  • Method: Treat intact VLPs with proteases and analyze fragmentation patterns

  • Interpretation: Unexpected cleavage patterns suggest improper orientation

  • Solution: Redesign construct with alternative signal peptides or membrane anchors

• Functional Binding Assessment

  • Method: Measure binding to natural ligand (CD112) using SPR or cell-based assays

  • Interpretation: Reduced binding suggests improper folding or orientation

  • Solution: Test alternative expression conditions (temperature, pH) or host cell lines

Functionality Troubleshooting Decision Tree:

• Issue: No detectable binding to CD112

  • Test: Verify PVRIG expression by Western blot

    • If negative: Check expression vector and transfection efficiency

    • If positive: Proceed to conformation analysis

  • Conformation Analysis: Use conformation-specific antibodies

    • If negative: Test protein folding enhancers (lower temperature, chemical chaperones)

    • If positive: Check ligand quality and assay conditions

• Issue: Weak binding affinity compared to cellular PVRIG

  • Test: Assess post-translational modifications

    • If abnormal: Switch to expression system with appropriate modification capabilities

    • If normal: Examine membrane composition of VLPs

  • Membrane Analysis: Compare lipid composition to natural cell membranes

    • If different: Supplement with specific lipids during VLP formation

    • If similar: Evaluate PVRIG density on VLP surface

• Issue: Inconsistent functional results

  • Test: Check VLP homogeneity

    • If heterogeneous: Improve purification strategy

    • If homogeneous: Assess PVRIG stability during storage

  • Stability Testing: Monitor functionality over time under different conditions

    • If declining: Optimize buffer composition and storage conditions

    • If stable: Standardize functional assay protocols

Advanced Solutions for Persistent Issues:

• Construct Modification Strategies:

  • Incorporate glycosylphosphatidylinositol (GPI) anchors for consistent orientation

  • Test chimeric constructs with well-characterized transmembrane domains

  • Implement leucine zipper domains to enhance correct assembly

• Membrane Engineering Approaches:

  • Supplement host cells with specific lipids to mimic native membrane environments

  • Co-express membrane-organizing proteins to create optimal microdomains

  • Use detergent-resistant membrane fractions for VLP budding

• Analytical Method Enhancement:

  • Implement hydrogen-deuterium exchange mass spectrometry to map exposed regions

  • Use single-molecule FRET to analyze protein dynamics on VLP surface

  • Apply cryo-electron microscopy for structural validation

By implementing this systematic troubleshooting approach, researchers can efficiently identify and resolve orientation and functionality issues with PVRIG-VLPs, ensuring reliable and reproducible results in downstream applications.

What are the relative advantages and limitations of different expression systems for producing PVRIG-VLPs?

Different expression systems offer distinct advantages and limitations for PVRIG-VLP production:

Decision Framework for Selecting Expression System:

• When native conformation is critical: HEK293 cells are the optimal choice, as they provide the most authentic representation of PVRIG in its native environment .

• For large-scale production: CHO cells offer the best balance of authenticity and scalability for applications requiring substantial amounts of material.

• For rapid screening: Insect cells or E. coli (for soluble domains) provide faster turnaround times for initial construct validation.

• For cost-sensitive applications: Yeast or E. coli systems significantly reduce production costs but sacrifice conformational authenticity.

• For clinical development: HEK293 or CHO systems with established GMP protocols offer the most straightforward path to clinical applications.

Current research demonstrates that HEK293-derived PVRIG-VLPs have proven most successful for applications requiring native conformation, including antibody development, functional assays, and immunological studies .

How do post-translational modifications affect PVRIG functionality in different expression systems, and what strategies can optimize these modifications?

Post-translational modifications (PTMs) significantly impact PVRIG functionality, with expression system-specific effects:

N-Glycosylation Effects on PVRIG Function:

Disulfide Bond Formation:
PVRIG contains multiple disulfide bonds critical for structural integrity. Expression systems differ in their ability to form correct disulfide patterns:

• HEK293/CHO: Efficient disulfide formation in the ER with proper isomerization

• Insect Cells: Generally efficient but may yield alternative patterns under high expression

• Yeast: Can form incorrect patterns due to different ER redox environment

• E. coli: Requires specialized strains or refolding protocols

Optimization Strategies for Disulfide Formation:

• Co-express protein disulfide isomerases (PDI) to enhance correct pairing

• Optimize redox conditions during protein expression

• Implement slow refolding protocols for inclusion body-derived material

• Consider adding chemical oxidants during purification to stabilize correct patterns

Lipid Modifications and Membrane Integration:
PVRIG function depends on proper membrane integration, influenced by:

• Lipid Environment: Expression systems differ in membrane composition

• Transmembrane Domain Interactions: System-specific lipid interactions affect receptor clustering

• Membrane Microdomain Formation: Glycolipid and cholesterol content varies between systems

Strategies for Optimizing Membrane Integration:

• Supplement host cells with specific lipids (cholesterol, sphingolipids) during VLP formation

• Engineer chimeric transmembrane domains optimized for specific expression systems

• Co-express lipid-modifying enzymes to generate appropriate membrane environments

• Use detergent-resistant membrane fractions for VLP formation

Phosphorylation Considerations:
While less studied for PVRIG, potential regulatory phosphorylation sites may affect function:

• Mammalian Systems: Provide physiologically relevant kinase activities

• Non-Mammalian Systems: May lack specific kinases for proper regulation

Protocol for Optimizing PTMs in PVRIG-VLP Production:

• Analysis Phase:

  • Map PTMs in native PVRIG using mass spectrometry

  • Identify critical modifications affecting function

  • Determine system-specific modification patterns

• System Selection:

  • Choose HEK293 cells for most authentic PTM profile

  • Consider glycoengineered CHO for large-scale applications

  • Use site-directed mutagenesis to eliminate non-essential glycosylation sites

• Process Optimization:

  • Adjust culture conditions to enhance desired modifications

  • Implement feeding strategies to provide PTM precursors

  • Control temperature and pH to optimize modification enzyme activity

• Validation:

  • Compare binding kinetics with native PVRIG

  • Assess thermal stability profiles

  • Evaluate immunological recognition

By systematically addressing PTM differences between expression systems, researchers can maximize PVRIG functionality in VLP systems for various applications.